MARK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL232042	1.00	5/20
SCHEMBL231766	0.79	5/20
Linifanib (SCHEMBL93804)	1.00	4/20
SCHEMBL234334	1.00	4/20
Ucn-01 (SCHEMBL259162)	1.00	4/20
SCHEMBL147422	0.66	4/20
SCHEMBL144979	0.56	4/20
SCHEMBL95142	1.00	3/20
SCHEMBL232936	0.79	3/20
SCHEMBL94964	0.79	3/20
SCHEMBL299518	0.76	3/20
SCHEMBL233442	0.75	3/20
SCHEMBL171201	0.69	3/20
SCHEMBL146734	0.67	3/20
SCHEMBL144651	0.67	3/20
SCHEMBL146677	0.67	3/20
SCHEMBL144378	0.66	3/20
SCHEMBL142020	0.65	3/20
SCHEMBL148704	0.62	3/20
SCHEMBL147730	0.61	3/20

Clinical trials — most relevant to MARK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia	PHASE2	COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis	PHASE1/PHASE2	COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Effect of Age on Glucose and Lipid Metabolism	nan	COMPLETED
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Immune Cell Response to Stimuli	nan	RECRUITING
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Novel Therapy for Glucose Intolerance in HIV Disease	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
Biomarkers in Samples From Patients With Endometrial Cancer	nan	WITHDRAWN
Multi-Tracer PET Quantitation of Skeletal Muscle Insulin Resistance in Type 2 Diabetes Mellitus	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a MARK2 binder may also engage these)

Protein	Name	Similarity
Q05512	—	1.000	Q05512 →
O08679	—	1.000	O08679 →
O08678	—	1.000	O08678 →
Q03141	—	1.000	Q03141 →
MARK1	Serine/threonine-protein kinase MARK1	1.000	landscape →
Q8VHJ5	—	1.000	Q8VHJ5 →
MARK3	MAP/microtubule affinity-regulating kinase 3	1.000	landscape →
Q8VHF0	—	1.000	Q8VHF0 →
Q2QMH1	—	1.000	Q2QMH1 →
Q19469	—	1.000	Q19469 →
A0A1D9QMS2	—	0.997	A0A1D9QMS2 →
Q8CIP4	—	0.997	Q8CIP4 →
O75011	—	0.997	O75011 →
Q8RX66	—	0.997	Q8RX66 →
P48479	—	0.997	P48479 →
P52497	—	0.997	P52497 →
O43078	—	0.996	O43078 →
PAK3	Serine/threonine-protein kinase PAK 3	0.996	landscape →
P06782	—	0.995	P06782 →
U4PR86	—	0.995	U4PR86 →
A2QHV0	—	0.995	A2QHV0 →
Q9LV37	—	0.995	Q9LV37 →
Q9CAU7	—	0.995	Q9CAU7 →
Q7RZD3	—	0.995	Q7RZD3 →
B3M301	—	0.994	B3M301 →
P24583	—	0.994	P24583 →
Q9URY1	—	0.994	Q9URY1 →
B4NBP4	—	0.994	B4NBP4 →
P40433	—	0.994	P40433 →
Q0CLX3	—	0.994	Q0CLX3 →